[ad_1]
More than 30,000 people participated in vaccine trials in the United States.
The vaccine can prevent COVID-19 disease, including severe illness, according to Moderna.
The effectiveness of the American biotechnology company Moderna Inc. The vaccine against the coronavirus COVID-19 is currently 94.5%. This was reported on the company’s website on Monday, November 16.
Moderna … announced today that the Independent Monitoring Board … of the third phase of its study of its possible COVID-19 mRNA-1273 vaccine has notified Moderna that the trials meet the statistical criteria defined in the study protocol efficacy and that the vaccine is (of) 94 effective. 5%, “the statement said.
It is observed that during the tests in the United States with the participation of more than 30 thousand people, the COVID-19 infection was detected (in an intermediate stage) in only 95 people. At the same time, 90 cases fell into the control group, whose representatives were injected with placebo instead of mRNA-1273.
Among those who were actually vaccinated, only five people were infected, which shows the high effectiveness of the vaccine. At the same time, among the five vaccinated patients, none of the disease was serious, while in the control group there were 11 serious cases.
“This is a turning point in the development of our vaccine … The result of the interim analysis gave us the first clinical confirmation that our vaccine can prevent COVID-19 disease, including severe disease,” said the executive director of Modern, Stephan Bansel.
Moderna also noted that most trial participants survived the vaccination without noticeable side effects.
Recall that in August, the United States administration signed a contract with Moderna to purchase 100 million doses of an experimental coronavirus vaccine for more than $ 1.5 billion.
Moderna was also reported to be in talks to sell the coronavirus vaccine at $ 25-30 per dose. The course of your vaccines will cost between 50 and 60 dollars.
News of Correspondent.net on Telegram. Subscribe to our channel https://t.me/korrespondentnet
